Compass Therapeutics’ (CMPX) Buy Rating Reiterated at HC Wainwright

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the stock.

Compass Therapeutics Stock Performance

NASDAQ CMPX traded up $0.03 during trading hours on Tuesday, hitting $0.96. 84,752 shares of the company’s stock were exchanged, compared to its average volume of 420,973. The business’s 50 day moving average is $1.09 and its 200-day moving average is $1.47. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.66. The firm has a market capitalization of $131.82 million, a P/E ratio of -2.61 and a beta of 0.79.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities research analysts anticipate that Compass Therapeutics will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new stake in shares of Compass Therapeutics during the 1st quarter worth about $80,000. Simplicity Wealth LLC acquired a new position in Compass Therapeutics during the first quarter valued at approximately $80,000. SG Americas Securities LLC grew its stake in Compass Therapeutics by 22.7% during the fourth quarter. SG Americas Securities LLC now owns 47,624 shares of the company’s stock worth $74,000 after buying an additional 8,817 shares during the period. Panagora Asset Management Inc. acquired a new stake in shares of Compass Therapeutics in the second quarter worth $68,000. Finally, Rhumbline Advisers raised its stake in shares of Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.